-
Mr. Balázs Rozványi: The role of the Hungarian League Against Cancer in cancer control
Editor’s Note: The 2023 Chinese Congress of Holistic Integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023 Mr.Balázs Rozványi. Mr. Rozványi, who is the…
-
Current Situation of Cancer Care in Kazakhstan
Editor’s Note: 2023 Chinese Congress of Holistic integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023. Professor Aigul Shinbolatova from who is Kazakh Institute…
-
Vision and Perspectives in Global Cancer Control
Interview with Professor Eduardo Cazap Editor’s Note: 2023 Chinese Congress of Holistic Integrative Oncology (2023 CCHIO) will be held in Tianjin from November 16th to 19th, 2023. Professor Eduardo Cazap,…
-
Prof. Min-Shan Chen: The Key to Liver Cancer Control Lies in the Integration of Medical Concepts and Multidisciplinary Collaboration
Editor’s Note: The 2023 Chinese Congress on Holistic Integrative Oncology (CCHIO), organized by the China Anti-Cancer Association and hosted by Tianjin Medical University Cancer Hospital, will take place in Tianjin…
-
Prof. Zhong-Qiu Lin: Creating a Protective Umbrella for the Cancer Prevention and Treatment of Chinese Women
Protecting the health of Chinese women and providing a robust defense against gynecological cancer requires the integration of more resources and efforts in the field of gynecological cancer prevention and treatment. On the eve of the “2023 Chinese Congress on Holistic Integrative Oncology (2023 CCHIO),” Oncology Frontier interviewed Prof. Zhong-Qiu Lin, Chairman of the Cervical…
-
ESMO Hot Topic | Professor Han Liang : Phase III MATTERHORN Study on the Verge of Success, Significant Improvement in pCR with Neoadjuvant Durvalumab for Gastric Cancer
The 2023 ESMO Annual Meeting took place from October 20th to 24th in Madrid, Spain. As a highly authoritative annual event in the field of oncology, it unveils cutting-edge advancements in cancer research each year. In the gastric cancer domain this year, the global Phase III MATTERHORN study on the anti-PD-L1 monoclonal antibody durvalumab was…
-
ESMO Exclusive Interview | Professor Changsong Qi: CAR-T Therapy IM96 Shows Significant Antitumor Activity in Advanced Colorectal Cancer with GCC Expression
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting took place in Madrid, Spain, from October 20th to 24th. The Oncology Frontier team delved into the frontline, capturing international advancements and witnessing the strides made by China in the global oncology arena. Professor Changsong Qi from Peking University Cancer Hospital delivered a crucial oral…
-
ESMO 2023丨Professor Zhimin Shao: monarcE Study 5-Year Follow-Up Data Revealed, Sustained Benefit for Patients
The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy alone in HR+, HER2-high-risk early-stage breast cancer patients. Since the disclosure of relevant data in March 2020, the study results have been updated multiple times, establishing the…
Connecting Medical Expertise through Media